Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523250 · ClinicalTrials.gov registry record · Phase 2
Ocular Hypotensive Efficacy of AR-102
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00523250 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT00523250, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.
Interventions
- DRUG AR-102 0.003% Ophthalmic Solution
- DRUG AR-102 0.005% Ophthalmic Solution
- DRUG AR-102 0.01% Ophthalmic Solution
- DRUG AR-102 0.03% Ophthalmic Solution
- DRUG AR-102 Vehicle Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523250
The ClinicalTrials.gov registry entry for NCT00523250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AR-102 0.003% Ophthalmic Solution is the first listed.
NCT00523250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523250 about?
NCT00523250 is a clinical study titled "Ocular Hypotensive Efficacy of AR-102". A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be diffe...
What is the current status of trial NCT00523250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2007-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00523250?
The interventions under investigation include: AR-102 0.003% Ophthalmic Solution (DRUG), AR-102 0.005% Ophthalmic Solution (DRUG), AR-102 0.01% Ophthalmic Solution (DRUG), AR-102 0.03% Ophthalmic Solution (DRUG), AR-102 Vehicle Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT00523250?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.